Nanyang Biologics has signed an agreement with Equinix and Hewlett Packard Enterprise (HPE) to deliver Vecura, an AI-driven drug discovery platform, and to build a large-scale natural drug compound library in Singapore. The companies announced the exclusive Memorandum of Understanding (MOU) during the AI4Life Summit in Singapore on August 26, 2025.
According to Nanyang Biologics, Vecura is a proprietary as-a-service AI drug discovery platform designed to advance development of therapies derived from natural sources. The company reports that it has already compiled a library of over 50,000 unique organisms and their chemical compounds. Through this collaboration, Nanyang Biologics will optimize Vecura’s AI models for next-generation graphical processing unit (GPU) architectures and integrate the system across its global ecosystem.
Equinix will provide international-scale data center infrastructure, anchoring Vecura’s operations within Singapore’s sovereign digital platforms to ensure security and accessibility. HPE will supply the computing and AI infrastructure needed for high-performance, large-scale molecular screening, enabling the platform to process millions of natural compounds rapidly.
Giang Nguyen, CTO at Nanyang Biologics, provided specific technical comments: “NYB’s living library is continuously expanding, this process is creating a huge and growing database of potential therapeutic impact. To scale this effort, NYB has chosen to work with global leaders like Equinix and HPE who provide enterprise-grade infrastructure to power the Vecura platform. The support from these global giants forms the foundation of Vecura to enable the growth of NYB’s expanding compound library, reducing R&D costs and timelines while enabling breakthroughs in oncology, neuroscience, metabolic health, and beyond.”
HPE’s regional Managing Director, Khai Peng Loh, noted: “The convergence of artificial intelligence and biotechnology holds transformative potential for global healthcare. Our collaboration with NYB and Equinix marks a pivotal moment in accelerating drug discovery through scalable AI infrastructure. By powering Vecura with HPE’s AI infrastructure and computing, we’re enabling researchers to screen millions of natural compounds with unprecedented speed and precision.”
Nanyang Biologics reports that Vecura operates with 27 percent higher predictive accuracy and 64 times greater screening efficiency than traditional methods. The company claims this architecture reduces research and development costs by over 50 percent while maintaining flexibility for larger compound libraries and complex computational pipelines. Key features of the infrastructure include GPU-based compute for high-volume molecular screening, global connectivity for multi-institutional collaboration, direct secure data exchange within Equinix data centers, and energy-efficient design for data protection and sustainability.
While the primary application is accelerating drug discovery workflows, the platform also targets sectors such as healthcare, life sciences, and natural product development, as explicitly described in the announcement.
Source: Nanyang Biologics
